It’s been an important week with big developments in potential COVID-19 vaccines; News on how steroid therapy may help some COVID patients; There’s results from the Actemra trial in COVID pneumonia patients; News that sputum samples may be just as effective as nasopharyngeal samples for detecting SARS-CVv-2; And researchers have linked vaccination to reduced risks of Alzheimer disease.
At AAIC 2020, 2 presentations separately discussed observing a reduced risk of AD in patients who received the influenza and pneumonia vaccines.
The FDA has granted Breakthrough Therapy designation to AXS-05 (Axsome Therapeutics) for the treatment of Alzheimer disease (AD) agitation.
Among patients with overactive bladder (OAB), anticholinergic medication use appears to be associated with an increased risk of new onset dementia when compared with beta-3 agonist use, according to the findings of a retrospective population-based cohort study.
The FDA has granted Fast Track designation to PR006 (Prevail Therapeutics), an experimental gene therapy, to slow the progression of frontotemporal dementia with a GRN mutation.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.
A PDUFA target date of June 30, 2020 has been assigned to the application.
Number of hospital days up by more than 50 percent in AD patients initiating antipsychotic medication
The FDA has granted Fast Track designation to neflamapimod (EIP Pharma) for the treatment of dementia with Lewy bodies (DLB).
This week we talk about the resurrection of Biogen’s novel Alzheimer treatment; A “landmark” approval in cystic fibrosis; Expanded indication for Farxiga; The first topical minocycline formulation for acne vulgaris; and the Johnson & Johnson baby powder recall.
